Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G J Mufti

Showing results (191-200 of 202) with videos related to

Pageof 21
Sort By:
Ecancermedicalscience|January 26, 2012
Azacitidine prolongs overall survival and reduces infections and hospitalizations in patients with WHO-defined acute myeloid leukaemia compared with conventional care regimens: an updateP Fenaux, G J Mufti, E Hellström-Lindberg, et al.
Human Gene Therapy|March 1, 1997
Irradiated NC adenocarcinoma cells transduced with both B7.1 and interleukin-2 induce CD4+-mediated rejection of established tumorsJ A Gaken, S J Hollingsworth, W J Hirst, et al.
Leukemia|July 1, 2017
Preclinical modeling of myelodysplastic syndromesK Rouault-Pierre, S A Mian, M Goulard, et al.
Bone Marrow Transplantation|July 10, 2012
The impact of center experience on results of reduced intensity: allogeneic hematopoietic SCT for AML. An analysis from the Acute Leukemia Working Party of the EBMTS Giebel, M Labopin, M Mohty, et al.
Bone Marrow Transplantation|August 30, 2008
Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplantB E Shaw, G J Mufti, S Mackinnon, et al.
Bone Marrow Transplantation|August 6, 2013
Retrospective study of alemtuzumab vs ATG-based conditioning without irradiation for unrelated and matched sibling donor transplants in acquired severe aplastic anemia: a study from the British Society for Blood and Marrow TransplantationJ C Marsh, R M Pearce, M B C Koh, et al.
Leukemia|December 22, 2018
Late treatment-related mortality versus competing causes of death after allogeneic transplantation for myelodysplastic syndromes and secondary acute myeloid leukemiaJohannes Schetelig, Liesbeth C de Wreede, Michel van Gelder, et al.
Bone Marrow Transplantation|January 9, 2021
Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides and Sézary syndrome. An updated experience of the Lymphoma Working Party of the European Society for Blood and Marrow TransplantationE Domingo-Domenech, R F Duarte, A Boumedil, et al.
Leukemia|April 18, 2006
The JAK2 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrowW Ingram, N C Lea, J Cervera, et al.
Bone Marrow Transplantation|March 21, 2017
Long-term follow-up of a retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic transplantation from matched related donors in myelodysplastic syndromesR Martino, A Henseler, M van Lint, et al.
Pageof 21

Showing results (191-200 of 202) with videos related to

Sort By:
Pageof 21
Ecancermedicalscience|January 26, 2012
Azacitidine prolongs overall survival and reduces infections and hospitalizations in patients with WHO-defined acute myeloid leukaemia compared with conventional care regimens: an updateP Fenaux, G J Mufti, E Hellström-Lindberg, et al.
Human Gene Therapy|March 1, 1997
Irradiated NC adenocarcinoma cells transduced with both B7.1 and interleukin-2 induce CD4+-mediated rejection of established tumorsJ A Gaken, S J Hollingsworth, W J Hirst, et al.
Leukemia|July 1, 2017
Preclinical modeling of myelodysplastic syndromesK Rouault-Pierre, S A Mian, M Goulard, et al.
Bone Marrow Transplantation|July 10, 2012
The impact of center experience on results of reduced intensity: allogeneic hematopoietic SCT for AML. An analysis from the Acute Leukemia Working Party of the EBMTS Giebel, M Labopin, M Mohty, et al.
Bone Marrow Transplantation|August 30, 2008
Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplantB E Shaw, G J Mufti, S Mackinnon, et al.
Bone Marrow Transplantation|August 6, 2013
Retrospective study of alemtuzumab vs ATG-based conditioning without irradiation for unrelated and matched sibling donor transplants in acquired severe aplastic anemia: a study from the British Society for Blood and Marrow TransplantationJ C Marsh, R M Pearce, M B C Koh, et al.
Leukemia|December 22, 2018
Late treatment-related mortality versus competing causes of death after allogeneic transplantation for myelodysplastic syndromes and secondary acute myeloid leukemiaJohannes Schetelig, Liesbeth C de Wreede, Michel van Gelder, et al.
Bone Marrow Transplantation|January 9, 2021
Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides and Sézary syndrome. An updated experience of the Lymphoma Working Party of the European Society for Blood and Marrow TransplantationE Domingo-Domenech, R F Duarte, A Boumedil, et al.
Leukemia|April 18, 2006
The JAK2 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrowW Ingram, N C Lea, J Cervera, et al.
Bone Marrow Transplantation|March 21, 2017
Long-term follow-up of a retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic transplantation from matched related donors in myelodysplastic syndromesR Martino, A Henseler, M van Lint, et al.
Pageof 21